The Union Health Ministry has prohibited the distribution and sale of anti-histamine drug Buclizine as an appetite stimulant "in public interest" under the Drugs and Cosmetics Act.
The drug will, however, be allowed to be marketed for "symptomatic treatment of various allergic conditions (rhinitis, conjunctivitis and urticaria) and for prevention and treatment of motion sickness."
Disclaimer: No Business Standard Journalist was involved in creation of this content